The clinical impact and outcomes of immunohistochemistry-only metastasis in breast cancer

Am J Surg. 2010 Sep;200(3):368-73. doi: 10.1016/j.amjsurg.2009.10.016.

Abstract

Background: Modern surgical and pathological techniques can detect small-volume axillary metastases in breast cancer with unknown clinical significance.

Methods: A retrospective database review from 1996 through 2004 identified all patients with immunohistochemical (IHC)-only sentinel node (IHC-SN) metastases and compared them with negative controls (Neg-SN).

Results: When comparing the 232 IHC-SN patients with the 252 Neg-SN controls, the IHC-SN patients had larger tumors, more lobular histology, a higher grade, and more HER2/neu positivity. They also received more systemic therapy. With a median follow-up of 5 years, there were no differences in recurrence-free survival or overall survival. In 123 IHC-SN patients treated with axillary dissection (axillary lymph node dissection), 16% had positive non-SLNs. Patients with positive non-SLNs tended to have worse outcomes.

Conclusions: IHC-only sentinel lymph node (SLN) metastases were associated with worse prognostic features and higher rates of systemic therapy. However, no outcomes differences were noted.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Axilla / pathology*
  • Breast Neoplasms / pathology*
  • Case-Control Studies
  • Chi-Square Distribution
  • Female
  • Humans
  • Immunohistochemistry / methods*
  • Lymph Node Excision
  • Lymphatic Metastasis / diagnosis*
  • Lymphatic Metastasis / pathology
  • Middle Aged
  • Prognosis
  • Proportional Hazards Models
  • Retrospective Studies
  • Risk Factors
  • Sentinel Lymph Node Biopsy